Pericarditis Drugs Market Introduction
Pericarditis is the inflammation of the pericardium. Pericardium is two thin layers of a sac like structure of tissues that surrounds the heart. The pericardium holds the heart in place and helps it work. It is a small amount of fluid that keeps both the layers separated from each other so that there is no friction between the layers. Pericarditis often causes chest pain and other symptoms too. The harsh chest pain associated with pericardium occurs when the layers of the pericardium rub against each other. Pericarditis usually begins suddenly but does not last for long.
When symptoms related to pericarditis develops more gradually or persists, it is considered as chronic pericarditis. Most cases of pericarditis are mild and usually improve on their own. The common symptoms related to pericarditis include cough; leg or abdominal swelling; low-grade fever; heart palpitations; shortness of breath when reclining; an overall sense of weakness, feeling sick or fatigue; and sharp, piercing chest pain. Pericarditis can be diagnosed with the help of electrocardiogram results, echocardiogram, physical examination, cardiac MRI, and reported symptoms.
Pericarditis Drugs Market – Competitive Landscape
Hoffmann-La Roche AG
Founded in 1896, F. Hoffmann-La Roche AG is headquartered in Basel, Switzerland. It is a global biopharmaceutical company engaged in the development, manufacture, and commercialization of pharmaceutical products and medical devices. Roche Pharmaceuticals is a world leader in biotechnology and oncology.
Identify the key factors that will drive your company’s growth, Request a brochure of this report here
Incorporated in 1863, Bayer AG is based in Leverkusen, Germany. It is a chemical and pharmaceutical company that markets products, helping prevent, diagnose, and treat diseases for humans and animals. The pharmaceutical division emphasizes on prescription products and specialty therapeutics in the areas of cardiology, women’s health, hematology, oncology, and ophthalmology.
Established in 1849, Pfizer Inc. is based in New York, U.S. It is a global pharmaceutical company that develops, manufactures, and markets prescription medicines in 11 therapeutic segments including cardiovascular, oncology, neuroscience, pain, infectious diseases, etc. The company offers a wide range of medicines and vaccines as well as consumer health care products for the prevention and treatment of infectious and chronic diseases for all age groups.
AstraZeneca was formed in 1999 through the merger of Sweden-based Astra AB and the U.K.-based Zeneca Group. AstraZeneca is a pharmaceutical company engaged in the discovery, manufacture, distribution, and commercialization of pharmaceutical products. The company is engaged in a single business activity of biopharmaceuticals through which it offers solutions for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
Pericarditis Drugs Market Dynamics
Rise in Prevalence of Pericarditis and Cardiovascular Diseases Driving Demand for Pericarditis Drugs
Increase in prevalence of cardiovascular diseases and pericarditis expected to drive the demand for pericarditis drugs. According to Cureus, an open access medical journal for a new generation of doctors and patients, acute pericarditis is the most common disease in several clinical settings. The incidence of acute pericarditis is recorded between 0.1% to 0.2% of hospitalized patients, and 5% of the patients admitted to the emergency department with non-ischemic chest pain. Furthermore, 17.9 million people die worldwide each year from cardiovascular diseases, an estimated 31% of all deaths worldwide. About more than 75% of cardiovascular deaths occur in low and middle income countries.
Expanding operations in future? To get the perfect launch ask for a custom report here
Key players in the market are focusing on the development of novel and effective drugs for pericarditis treatment
A key factor propelling the growth of the global pericarditis drugs market is the adoption of dual therapy for the treatment of idiopathic pericarditis. Conventionally, aspirin as monotherapy is used to treat acute pericarditis. However, clinical trials are being carried out for dual therapy with the combination of two drug aspirin with colchicine for the treatment of pericarditis. The results have shown that combination therapy is effective in reducing the recurrence rate of pericarditis as compared to conventional monotherapy.
Therefore, use of dual therapy such as aspirin with colchicine is anticipated to increase with rise in prevalence of idiopathic pericarditis with repeated episodes. However, few side effects of anti-inflammatory drugs, presence of misbranded drugs, surgical intervention, and stringent government rules are expected to hinder the growth of the global pericarditis drugs market during the forecast period.
Pericarditis Drugs Market – Segmentation
The pericarditis drugs market can be bifurcated on the basis of:
- Drug Type
- Distribution Channel
Pericarditis Drugs Market Segmentation – By Drug Type
Depending on the drug type, the pericarditis drugs market can be divided into:
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
Pericarditis Drugs Market Segmentation – By Distribution Channel
On the basis of the distribution channel, the pericarditis drugs market can be fragmented into:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.